Treatment of CAR T cells with BET inhibitor JQ1 promoted the expansion of less differentiated TSCM and TCM, downregulated PD-1 and TET2 exhaustion marker expression, improved persistence and effector function, and augmented T-cell mediated anti-tumor effect in leukemia models (44, 45). Here, TET2 is linked to neoplasm.